<DOC>
	<DOC>NCT01666977</DOC>
	<brief_summary>The purpose of this phase 1b/2 study is to estimate the treatment effect of study drug measuring progression free survival.</brief_summary>
	<brief_title>Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>To evaluate the incidence of adverse events and clinical laboratory abnormalities defined as dose-limiting toxicity in subjects with metastatic non-squamous non-small cell lung cancer (NSCLC) treated with AMG 386 in combination with pemetrexed and carboplatin</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirmed, unresectable stage IV nonsquamous non small cell lung cancer (NSCLC) Radiographically evaluable disease (measurable or nonmeasurable) per RECIST 1.1 with modifications Adequate hematological, renal, and hepatic function, normal coagulation profile, calculated CrCL â‰¥ 45 mL/min Other criteria may apply Any prior chemotherapy or targeted therapy for nonsquamous NSCLC Subjects with adenosquamous histology or any histology subtype containing greater than 10% squamous cells Subjects with an epidermal growth factor receptor (EGFR) mutation sensitive to treatment with a tyrosine kinase inhibitor (TKI) Subjects with known anaplastic lymphoma kinase (EML4ALK) translocations History or presence of central nervous system metastases Central (chest) radiation therapy within 28 days prior to enrollment/randomization, radiation therapy to any other site(s) within 14 days prior to enrollment/randomization History of pulmonary hemorrhage or gross hemoptysis within 6 months History of arterial or venous thromboembolism within 12 months History of clinically significant bleeding within 6 months Clinically significant cardiovascular disease within 12 months Other criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>